Anesiva Begins Phase II Adlea Trial
Anesiva has started a Phase II clinical trial of Adlea, its nonopioid drug, for the management of acute pain in South Korean patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.
In the U.S., the surgery is often conducted on an outpatient basis. In South Korea, patients are routinely hospitalized for up to two days, which allows for more extensive near-term follow-up, Anesiva said.
The multicenter, randomized, double-blind, dose-escalating, placebo-controlled study is evaluating the safety, tolerability, efficacy and pharmacokinetics of a single, injected dose of the drug after the surgical wound has closed.